Avantor

Avantor beat analyst estimates in the second quarter on both revenue (USD 1.69 billion) and adjusted diluted EPS (USD 0.21). Management raised the full-year guidance for adjusted EPS to USD 0.80–0.83, which fueled the premarket price move. The positive reaction is seen as a sign that the restructuring program "Revival" is delivering initial financial improvements; the stock was trading at USD 13.00, still below its 52-week high. » More on de.investing.com

Longleaf Partners highlighted Avantor as a contributor in Q2 2026, noting signs of stabilization and new CEO Emmanuel Ligner's guidance for revenue growth and strong free cash flow generation in 2H26. Book-to-bill exceeded one and management has progressed on operational initiatives, including a redesigned VWR website and improved ship-to-order patterns in Bioprocessing. Avantor closed at $10.39 on July 10, has a market cap of $7.09 billion, and has seen mixed recent performance with a one-month gain but a large 52-week decline. » More on finance.yahoo.com

Avantor appointed Ludovic Brellier as Executive Vice President of Bioscience & Medtech Products and Chief Transformation Officer, effective May 1. Brellier will run growth and operations for the BMP business and lead the enterprise-wide Revival Management Office, drawing on his prior leadership at Danaher and Cytiva. Benoit Gourdier will remain through end of 2026 to ensure an orderly transition, and CEO Emmanuel Ligner said Brellier’s transformation experience will support the company’s strategic initiatives. » More on finance.yahoo.com